ACAD vs RJF · P/E 15, rev $576.0M vs rev $15.91B
ACADIA Pharmaceuticals Inc (ACAD) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
RJF (RJF) common stock.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. RJF currently screens at market cap $0.
Not investment advice. Open the ACAD and RJF stock pages for the full models.
Not investment advice.